Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lipoprotein Particle Size Predicts Development of Diabetes

By LabMedica International staff writers
Posted on 24 Aug 2010
The size and concentration of lipoproteins in the blood can help determine whether a patient will develop diabetes mellitus type 2. More...


The lipoprotein particle size and concentration can be measured by nuclear magnetic resonance (NMR) spectroscopy. This technique simultaneously quantifies the size and concentration of lipoprotein particles expressed each as an average particle size in nanometers or as lipoprotein particle concentration (in particle mol/L).

A prospective study, carried out at the Harvard Medical School, (Boston, MA, USA), followed 26,836 initially healthy women for 13 years for incident type-2 diabetes. During that time, 1,687 developed the disease. The study found that larger low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particles were associated with lower risk, and smaller LDL and HDL particles were associated with higher risk of diabetes. Even in women with normal triglyceride and HDL cholesterol measured by standard tests, having smaller LDL particles imparted higher risk of diabetes.

Doctors typically look for increases in glucose and triglycerides, and decreases in HDL cholesterol, to determine if a patient is becoming prediabetic. Even before changes in glucose levels are detectable, there are significant changes in the metabolism of cholesterol and triglycerides. These standard lipid tests quantify the cholesterol or triglyceride content of lipoproteins, without providing size-specific lipoprotein particle information. NMR lipoproteins examined in individuals with insulin resistance or type-2 diabetes with small LDLs, small HDLs, and large very low-density lipoproteins (VLDLs) associated positively and large HDLs associated inversely with insulin resistance measured by the euglycemic clamp technique or the frequently sampled intravenous glucose tolerance test .

Samia Mora, M.D., of Harvard Medical School, said, "Our findings indicate for the first time that even before the onset of clinical type 2 diabetes, the size and number of the lipoprotein particles may indicate which women go on to develop future disease. This could provide an important opportunity for a woman with a normal blood glucose, but an abnormal NMR lipoprotein test result, to intervene early by following a healthy diet, losing weight, and increasing her physical activity level, all known ways to reduce her chance of developing diabetes even years before she gets a high glucose reading.” The results of the study were published in May 2010 issue of Diabetes.

Related Links:

Harvard Medical School




Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.